Shilpa Medicare gets CDSCO approval for Tranexamic Acid Spray; stock zooms ~3%

20 Sep 2022 , 09:15 AM

Shilpa Medicare Limited announced that its successful innovation of the first in world topical hemostatic spray of Tranexamic Acid has received CDSCO approval.

This innovative spray formulation is simple, easy to transport, easy to apply, and a lifesaving instrument. It is clinically proven in humans and validated in a robust swine trauma model.

The medicine is certified for use in minimising or avoiding haemorrhage, as well as lowering the need for replacement treatment in cases of accidental or domestic damage.

Civilian prehospital care, emergency medical systems (EMS), and ambulance supplies benefit from this development. Due to its usage, there are fewer chances of bleeding during transport to the hospital.

Patents have been awarded in India until 2037, and in the United States, Australia, Russia, and South Africa until 2038. Shilpa is always pursuing patent prosecution in other countries and seeking further protection, said the company in a regulatory filing.

At around 9.18 AM, Shilpa Medicare was trading at Rs386.30 up by 2.9% from its previous closing of Rs375.40 on the BSE.

For feedback and suggestions, write to us at [e-mail]